Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer

OBJECTIVES:

• Determine the feasibility of performing minimally invasive esophagectomy (MIE), in terms of 30-day mortality, in patients with high-grade dysplasia of the esophagus or stage I-III esophageal cancer.
• Determine the complications associated with this procedure in these patients.
• Determine the rate at which conversion to open operation is required in patients undergoing this procedure.
• Determine the length of the operation, duration of intensive care unit stay, and length of hospital stay in patients undergoing this procedure.
• Determine feasibility and conversion rate of MIE after neoadjuvant therapy.
• Assess the effectiveness of lymph node dissection by MIE by recording the total number of lymph nodes dissected.
• Assess outcomes at follow-up to three years.

OUTLINE: This is a multicenter study.

Patients undergo minimally invasive esophagectomy comprising video-assisted thoracoscopy to mobilize the thoracic esophagus in combination with laparoscopy to complete the esophagectomy and a neck incision to mobilize the cervical esophagus. Mortality at 30 days is assessed.

Patients are followed every 3 months for 2 years and then every 6 months for 1 year.

ACTUAL ACCRUAL: A total of 110 patients were accrued for this study.

Inclusion criteria

DISEASE CHARACTERISTICS:

• High grade dysplasia of the esophagus who would undergo esophagectomy OR esophageal cancer at stage T1-T3, N0-N1 who require esophagectomy (patients with M1 disease and/or bulky lymph node involvement were excluded).
• Pathological confirmation of a diagnosis of cancer or high-grade dysplasia of the esophagus by biopsy.
• Computerized tomography (CT) scan of chest and abdomen within 6 weeks prior to registration
• Stomach must be available for conduit
• Age of 18 and over
• ECOG performance status of 0-2
• Creatinine less than 2 mg/dL
• Patients with esophageal cancer who would be treated with neoadjuvant chemotherapy and/or radiation were eligible. If patients were registered prior to receiving neoadjuvant chemotherapy they were allowed up to 5 months to complete therapy and any restaging that was necessary before operation was performed.
• The patient was considered an appropriate candidate for surgery based on preoperative clinical staging and physiological factors prior to registration as documented in the surgical plan. Pre-operative staging should include:

• Endoscopic ultrasound (EUS)
• Positron emission tomography (PET) scan and/or laparoscopic staging (Laparoscopic staging could be performed on the day of resection. Additional evaluation was recommended if the PET scan suggested distant metastatic disease.)

Exclusion criteria

• Cancer extending into the stomach more than 20%
• Prior anti-reflux or gastric operations
• Prior right thoracotomy
• Prior major neck operation other than the removal of superficial skin lesion